Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: resembling (46)

Audit and Risk Committee ToR March 2026

Description: Audit and Risk Committee Terms of Reference Version: 8 Date Issued: Review Date: Document Type: 10 March 2026 January 2027 Committee
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2026-Trust-documents/Audit-and-Risk-Committee-ToR-March-2026.pdf

Ibrutinib-Venetoclax

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia IBRUTINIB-VENETOCLAX Regimen CLL – Ibrutinib & Venetoclax Indication • Ibrutinib plus Venetoclax is recommended as an option for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Ibrutinib-Venetoclax-Ver1.1.pdf

B-AVD (Brentuximab vedotin-Dacarbazine-Doxorubicin-Vinblastine)

Description: Chemotherapy Protocol LYMPHOMA BRENTUXIMAB VEDOTIN-DACARBAZINE-DOXORUBICIN-VINBLASTINE (B- AVD) Regimen • Lymphoma – Brentuximab vedotin - Dacarbazine-Doxorubicin-Vinblastine Indication • Previously untreated stage
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/B-AVD-Brentuximab-vedotin-Dacarbazine-Doxorubicin-Vinblastine.pdf

AmB-LISOCEL-Cyclophosphamide (300)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AmB – LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) Ambulatory Regimen This regimen is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-LISOCEL-Cyclophosphamide-300-Fludarabine-30.pdf

2025 WRES report and action plan

Description: Workforce Race Equality Standard Annual Report 2025 1 Executive Summary WRES Data has been submitted by the Trust since 2015 and
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/2025-wres-report-and-action-plan.pdf

BRC Research-imaging-proposal-form_v2 2025 FINAL

Description: BRC Research Imaging Proposal form The BRC Research Imaging Proposal form should be completed by the chief/principa
Url: /Media/Southampton-Clinical-Research/Downloads/BRC-Research-imaging-proposal-form-v2-2025-FINAL.docx

WGLS (combined) user handbook

Description: University Hospital Southampton NHS Foundation Trust DOC987 Revision 1/ WRGL 33687 V1.0 Wessex Genomics Laboratory Service Wessex Genomics Laboratory Service
Url: /Media/UHS-website-2019/Docs/Services/Pathology/WGLS-combined-user-handbook.pdf

Belantamab Bortezomib Dexamethasone Weekly

Description: Chemotherapy Protocol BELANTAMAB MAFODOTIN – BORTEZOMIB - DEXAMETHASONE This protocol may require funding Regimen • Belantamab Mafodotin – Bortezomib - Dexamethasone Indication • 1 previous line of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Belantamab-Bortezomib-Dexamethasone-Weekly-Ver1.pdf

Isatuximab VRD weekly

Description: Chemotherapy Protocol Myeloma Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-Dexamethasone (20) Regimen Myeloma – Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-Dexamethasone (20
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Isatuximab-VRD-weekly-Ver1.pdf

What to expect in the last days and weeks of life: When your loved one is staying in hospital - patient information

Description: This booklet provides information for family, friends and carers who will be supporting a loved one in hospital during their last
Url: /Media/UHS-website-2019/Patientinformation/Bereavement-and-end-of-life/What-to-expect-in-the-last-days-and-weeks-of-life-When-your-loved-one-is-staying-in-hospital-3684-PIL.pdf

601 to 610 of 761

Previous … 59 60 61 62 63 … Next